Cargando…

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer

Detalles Bibliográficos
Autores principales:	Dermime, Said, Merhi, Maysaloun, Merghoub, Taha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567164/ https://www.ncbi.nlm.nih.gov/pubmed/34745152 http://dx.doi.org/10.3389/fimmu.2021.781872

Ejemplares similares

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
por: Akbar, Shayista, et al.
Publicado: (2023)

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
por: Raza, Afsheen, et al.
Publicado: (2020)

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
por: Relecom, Allan, et al.
Publicado: (2021)

Editorial: Genomics, proteomics and immunological signatures as diagnostic, predictive, and prognostic biomarkers in head and neck cancers
por: Raza, Afsheen, et al.
Publicado: (2023)

Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report
por: Merhi, Maysaloun, et al.
Publicado: (2018)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review
por: Omar, Nabil E., et al.
Publicado: (2020)

Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
por: Jiang, Shuai, et al.
Publicado: (2022)

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
por: Wang, Jingting, et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy
por: Zappasodi, Roberta, et al.
Publicado: (2022)

Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors
por: Chong, Pei Pei, et al.
Publicado: (2022)

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
por: Seliger, Barbara
Publicado: (2019)

Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
por: Andersson, Patrik, et al.
Publicado: (2019)

Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
por: Fernandes, Queenie, et al.
Publicado: (2018)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
por: von Knethen, Andreas, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
por: Weber, Rebekka, et al.
Publicado: (2018)

Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer
por: Raza, Afsheen, et al.
Publicado: (2022)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
por: Song, Yuxiao, et al.
Publicado: (2020)

Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry
por: Ma, Weijie, et al.
Publicado: (2023)

Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
por: Gibellini, Lara, et al.
Publicado: (2020)

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
por: Yang, Qiao, et al.
Publicado: (2021)

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types
por: Shang, Xiaoling, et al.
Publicado: (2022)

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2023)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer
por: Yamashita, Hitomi, et al.
Publicado: (2017)

Editorial: Soluble immune checkpoints: Novel physiological immunomodulators
por: Riva, Antonio
Publicado: (2023)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets
por: Campesato, Luis F., et al.
Publicado: (2020)

Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors
por: Giordan, Quentin, et al.
Publicado: (2021)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation
por: Siveen, Kodappully S., et al.
Publicado: (2019)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments
por: Liao, Ping, et al.
Publicado: (2023)

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2022)

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
por: Ancel, Julien, et al.
Publicado: (2023)

Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis
por: Lopes, Sébastien, et al.
Publicado: (2023)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8aq815lta0na9fjegt9s9liajb